Echo IQ (ASX:EIQ) has presented at the Bell Potter Healthcare Conference 2026, disclosing details about its AI-powered echocardiography platform, management team, and clinical advisory board, according to a company filing released to the market in November 2026.
Key Points
- EIQ presented at the Bell Potter Healthcare Conference in November 2026, sharing details of its AI-based cardiac diagnostic technology.
- The company's platform captures measurements across echocardiogram images and maps them into a multi-dimensional AI model.
- EchoSolv HF is disclosed as an investigational device that has not been cleared or approved by the FDA and is not available for commercial distribution in the United States.
- The clinical advisory board collectively holds over 1,200 peer-reviewed journal publications and covers expertise across the US, Europe, and Asia Pacific.
AI Echocardiography Platform Overview
According to the filing, Echo IQ's platform captures measurement data across all echocardiogram images and maps them into a multi-dimensional AI model. The system examines aortic velocity and gradient data, alongside ventricular, atrial, pulmonary, and right heart measurement data, to determine the impact on the aortic valve area. The filing describes these measurements as being captured across all images before being processed through the company's AI model. The presentation was prepared as a summary and does not purport to be all-inclusive or complete, according to the filing's disclaimer.
Management Team Disclosed in Conference Presentation
The filing identifies Dustin Haines as Chief Executive Officer, disclosing that he brings 25 years of experience in leading global businesses in pharmaceuticals, biotechnology, and medical devices. The filing states that most recently Mr Haines was head of Asia, Middle East, Turkey, and Russia for Gilead Sciences, where he managed over US$1.2 billion in revenue. Additional management members disclosed include Matthew Dodds as Chief Financial Officer, Nick Lubbers as President and General Manager US, Sam Dribin as Chief Technology Officer, Patrick O'Shea as Head of Strategy and Operations, and Dane Brescacin as Senior Vice President of Regulatory Affairs.
Clinical Advisory Board and Regulatory Status
The filing discloses that Echo IQ's clinical advisory board comprises globally recognised experts in cardiovascular medicine, echocardiography, sonography, and applied AI, with public health expertise to assist with commercialisation across multiple jurisdictions. Named advisors include Professor Geoff Strange, PhD, described as creator, director and chief investigator of the National Echo Database of Australia and New Zealand, and Professor David Playford, MBBS, PhD, FRACP, described as Professor of Cardiology. The filing explicitly states that EchoSolv HF is an investigational device that has not been cleared or approved by the FDA and carries no assurance that clearance will be obtained.




Please wait processing your request...